Business Wire

SEOUL-SEMICONDUCTOR

29.10.2021 09:20:08 CEST | Business Wire | Press release

Share
In a Clinical Trial, Daytime Exposure to Short-Wavelength Enriched Light With Daylight-like Spectrum Improves Learning and Memory Function

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that following Seoul National University in Korea and Basel University in Europe, a research team found that exposure to short-wavelength enriched light with daylight-like spectrum improves key components of learning such as working memory, cognitive processing speed, and testing accuracy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211029005138/en/

The clinical trial began in 2019, conducted by the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, and included college-aged adults. The results from the study clearly showed the effectiveness of improving procedural learning.

Shadab Rahman, PhD MPH, a researcher in the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital and Assistant Professor of Medicine at Harvard Medical School, led the study along with Leilah Grant, PhD, Melissa St. Hilaire, PhD, Steven Lockley, PhD, and other researchers at the Brigham. Dr. Rahman said, “Even if the color temperature and brightness are the same, light with different spectra may affect non-visual responses to light exposure, including those of circadian rhythms and cognition, differently. In this experiment, we found improvement in working memory, cognitive processing speed, procedural learning, and testing accuracy with young adults under daylight-like light spectrum lighting compared to conventional-LED spectrum lighting. This is an important result that can inform lighting choices for indoor use to enhance students’ learning and memory function.”

The daylight-like spectrum lighting used in the study was provided by Seoul Semiconductor Co., Ltd., makers of SunLike. SunLike is an optical semiconductor technology that reproduces the natural sunlight spectrum curve, that is, the intensity of light for each wavelength of red, orange, yellow, green, blue, and purple. This new concept of LED light source embodies almost the same characteristics of natural light and is optimized for human 24-hour circadian rhythm accordingly.

There has been an increase in research activity on the relationship between light and human bio-function, including a recent scientific study focusing on the effects of light spectrum on sleep quality, visual comfort, well-being and daytime alertness conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland, entitled: ‘Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,’ published in the Journal of Lighting and Research Technology on March 24, 2019. In addition, in an experiment at Seoul National University College of Medicine in July 2018, it was demonstrated that vitality and alertness were increased when SunLike LED lighting was used.

“As the saying goes, ‘Mother Nature is great’, the human body has a 24-hour circadian clock that has evolved to set its time by tracking the daily cycle of sunlight. SunLike is a technology that reproduces all wavelengths of visible light as closely as possible to sunlight. We've been working on R&D over the past 30 years to optimize this technology to provide plants, animals and humans access to light that is closest to sunlight to promote healthy circadian rhythms and sleep, which can also help children and students to study effectively and maintain good health”, said Chung-hoon Lee, CEO of Seoul Semiconductor.

Seoul Semiconductor and Toshiba Materials were jointly involved in the development and release of SunLike in 2017, which has needed investment to further expand stable production and sales. As a result of continuous consultations between the two companies over the past two years to improve the speed of decision and operational efficiency for the SunLike business, Seoul Semiconductor has acquired all technologies, patents, trademarks, etc. related to SunLike, the light most similar to sunlight. Key workers from Toshiba Materials also joined Seoul Semiconductor, and they began efforts to expand sales from September.

About Seoul Semiconductor

Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en .

Link:

ClickThru

Social Media:

https://www.facebook.com/seoulsemiconductorglobal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical

OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 08:00:00 CEST | Press release

OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual

Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia10.8.2026 05:49:00 CEST | Press release

Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/ Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia to help families better manage their cash flow and spread pilgrimage costs responsibly. The solution is designed for eligible Muslims who have the means to undertake the pilgrimage but prefer to spread its cost over time. This flexibility enables individuals and families to manage their cash flow responsibly, maintain regular savings and preserve sufficient liquidity for emergencies and other financial obligations. The launch marks a significant milestone in Bettr’s Islamic finance initiative and

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release

An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr

Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 19:16:00 CEST | Press release

Canadian-led expansion will build the world’s largest and most capable C-130 airtanker fleet Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s g

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye